Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Jan 16, 2018
    TEL-AVIV, Israel and RALEIGH, N.C., Jan. 16, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, toda...
    PDF
    Dec 22, 2017
    YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinomaCholangiocarcinoma (bile duct cancer) is a highly lethal malignancy for which there is an urgent need for more effective treatments A Phase I clinical study with YELIVA® in patients with advanced solid tumor...
    PDF
    Dec 5, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, toda...
    PDF
    Nov 13, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 13, 2017
    RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017In addition, an underwritten public offering of the Company's American Depositary Shares (ADSs) is scheduled to be closed today, November 13, 2017, subject to customary terms and conditions, for aggregate net proceeds of approximately $20....
    PDF
    Nov 9, 2017
    Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn's disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active Crohn's disease Worldwide sales of Crohn's disease therap...
    PDF
    Nov 8, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 7, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 6, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Nov 6, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases...
    PDF
    Page:
    1
    ... NextLast

    Subscribe to press releases